J. Dugan

Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study

D. Hedeker, O. Olopade, P. Hulick, 2019, Cancer Medicine.

Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone

M. Caligiuri, G. Nuovo, G. Lozanski, 2018, Clinical Cancer Research.

Inhibitor of JAK2 CEP-33779, a Novel, Orally Active, Selective Treatment of Lupus Nephritis in Mice Using Depletion of Autoreactive Plasma Cells and

Mason, B. Ruggeri, D. Gingrich, 2011 .

Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders

Carrie B Coleman, B. Haverkos, J. Dugan, 2019, Front. Oncol..

Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.

K. Metzeler, A. Verma, G. Garcia-Manero, 2022, Journal of Clinical Oncology.

Emphysema with Placental Transmogrification and Lipomatous Change.

Shine Raju, Subha Ghosh, Sumanth Khadke, 2020, Radiology. Cardiothoracic imaging.

The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.

J. Moreb, Franklin L. Chen, A. Skarbnik, 2023, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

K. Metzeler, K. Götze, D. DeAngelo, 2022, HemaSphere.

Enasidenib for the treatment of acute myeloid leukemia

D. Pollyea, J. Dugan, 2018, Expert review of clinical pharmacology.